The advent of immune checkpoint inhibitors (ICIs) has marked a paradigm shift in cancer treatment, yet a significant portion of breast cancer patients fail to respond to these therapies.
Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial. Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results